Download the Report
China is refining incretins while the West builds around them
China-origin obesity drug sponsors are refining the incretin, while Western sponsors lean toward non-incretin, oral and muscle-sparing drugs. Sleuth’s June 2026 map covers more than 1,200 active obesity programs, preclinical through approved; among its 477 disclosed clinical-stage programs, 41% of China-origin programs are mono-GLP-1 drugs, against 18% of Western ones, and 53% of Western programs use a non-incretin mechanism, against 30% of China-origin ones. Sleuth’s reading is that the incretin is becoming a molecule to license, increasingly from China, and that the differentiation that earns premium valuations now sits in the non-incretin layer.
Chinese programs deepen the incretin, Western programs target its weak points
Of the 477 clinical-stage programs in the June 2026 analysis, 152 are China-origin and 325 are Western or from elsewhere. China-origin programs stay close to the incretin: besides the 41% that are mono-GLP-1, 24% are single-molecule multi-agonists (15% in the West) and 38% emphasize long-acting, low-frequency dosing (34%). That is the ground Eli Lilly and Novo Nordisk already hold at scale.
Western programs skew toward what incretins don’t solve: oral delivery (43%, against 32% of China-origin programs), muscle-sparing weight loss (26% against 16%) and first-in-class biology (28% against 9%). Those levers map to the reasons roughly 60% to 70% of patients leave GLP-1s within a year, including tolerability, lean-mass loss and adherence. Muscle sparing is filling fast, with programs from Lilly (through Versanis), Scholar Rock and Regeneron, and GSK’s May 2026 license of SiranBio’s ALK7-targeting oligonucleotide from China.
Chinese disclosure is thinner, so the non-incretin shares likely understate China and the gap is directional rather than exact. The origin split also differs from Sleuth’s GLP-1 Intelligence Report, Q3 2026, which counts GLP-1 and metabolic programs by company headquarters and finds Chinese developers well ahead of US developers on volume.
For a new entrant, another incretin competes with the incumbents and a queue of China-origin fast followers, while the differentiated positions sit outside the incretin class.
The non-incretin white space is uneven
Sleuth’s June 2026 map of non-incretin target clusters plots clinical maturity, the share of a cluster’s programs in the clinic or approved, against China-origin share. The muscle/activin and amylin/calcitonin clusters are the crowded giants: the two largest on the map, with dozens of programs each and China-origin shares of roughly a third.
FGF21, THR-beta and bile acid (TGR5/FXR) are among the more clinically mature clusters, with about 40% to 55% of programs in the clinic, and they lean Chinese, with China-origin shares of roughly 40% to 60%. A Western sponsor would enter them as a fast follower. GDF15/GFRAL and apelin also have high China-origin shares but are earlier.
The China-light clusters, with China-origin shares of about 15% or less, include MC4R/melanocortin, NPY/PYY and PTP1B, which are mostly preclinical, and NLRP3 and mitochondrial uncouplers, which are small but further along, with about half or more of their programs in the clinic.
Because much of this open ground is early, positioning depends on data points scattered across regional conferences, patents and company disclosures. The field in aggregate sets the context, but the position has to be mapped for a specific program.
Program counts and shares are as of June 2026 and cover disclosed programs, classified by originator company and primary mechanism. A program can appear in more than one non-incretin cluster, and cluster positions are approximate readings from the chart.
Frequently asked questions about China and Western obesity pipelines
How many obesity drugs are in development?
Sleuth mapped more than 1,200 active obesity programs, from preclinical through approved, in June 2026. Of the 477 disclosed clinical-stage programs, 152 are China-origin and 325 are Western or from elsewhere.
How do Chinese and Western obesity pipelines differ?
In Sleuth’s June 2026 analysis, 41% of China-origin clinical-stage programs are mono-GLP-1, against 18% of Western programs. Western programs lean toward non-incretin mechanisms (53% against 30%), oral delivery (43% against 32%) and muscle sparing (26% against 16%).
Where is the white space in non-incretin obesity drugs?
As of June 2026, the clusters with low China-origin shares include MC4R/melanocortin, NPY/PYY and PTP1B, which are mostly preclinical, and NLRP3 and mitochondrial uncouplers, which are small but further along. Muscle/activin and amylin are crowded, and FGF21, THR-beta and bile acid lean Chinese.
Why are Western obesity programs focused on oral and muscle-sparing drugs?
They target the reasons roughly 60% to 70% of patients stop GLP-1s within a year, including tolerability, lean-mass loss and adherence. In June 2026, 43% of Western clinical-stage programs emphasized oral delivery and 26% muscle sparing.
